Chronic widespread pain in spondyloarthritis

Fabiola Atzeni, L. Boccassini, M. Di Franco, A. Alciati, A. Marsico, M. Cazzola, G. Cassisi, P. Sarzi-Puttini

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The pain associated with spondyloarthritis (SpA) can be intense, persistent and disabling. It frequently has a multifactorial, simultaneously central and peripheral origin, and may be due to currently active inflammation, or joint damage and tissue destruction arising from a previous inflammatory condition. Inflammatory pain symptoms can be reduced by non-steroidal anti-inflammatory drugs, but many patients continue to experience moderate pain due to alterations in the mechanisms that regulate central pain, as in the case of the chronic widespread pain (CWP) that characterises fibromyalgia (FM). The importance of distinguishing SpA and FM is underlined by the fact that SpA is currently treated with costly drugs such as tumour necrosis factor (TNF) inhibitors, and direct costs are higher in patients with concomitant CWP or FM than in those with FM or SpA alone. Optimal treatment needs to take into account symptoms such as fatigue, mood, sleep, and the overall quality of life, and is based on the use of tricyclic antidepressants or selective serotonin reuptake inhibitors such as fluoxetine, rather than adjustments in the dose of anti-TNF agents or disease-modifying drugs.

Original languageEnglish
Pages (from-to)28-32
Number of pages5
JournalReumatismo
Volume66
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Fibromyalgia
Chronic Pain
Pain
Tumor Necrosis Factor-alpha
Pharmaceutical Preparations
Social Adjustment
Tricyclic Antidepressive Agents
Fluoxetine
Serotonin Uptake Inhibitors
Fatigue
Sleep
Anti-Inflammatory Agents
Joints
Quality of Life
Inflammation
Costs and Cost Analysis
Therapeutics

Keywords

  • Ankylosing spondylitis disease activity score
  • Bath ankylosing spondylitis disease activity index
  • Disease activity
  • Fibromyalgia
  • Prevalence
  • Spondyloarthritis

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Atzeni, F., Boccassini, L., Di Franco, M., Alciati, A., Marsico, A., Cazzola, M., ... Sarzi-Puttini, P. (2014). Chronic widespread pain in spondyloarthritis. Reumatismo, 66(1), 28-32. https://doi.org/10.4081/reumatismo.2014.761

Chronic widespread pain in spondyloarthritis. / Atzeni, Fabiola; Boccassini, L.; Di Franco, M.; Alciati, A.; Marsico, A.; Cazzola, M.; Cassisi, G.; Sarzi-Puttini, P.

In: Reumatismo, Vol. 66, No. 1, 2014, p. 28-32.

Research output: Contribution to journalArticle

Atzeni, F, Boccassini, L, Di Franco, M, Alciati, A, Marsico, A, Cazzola, M, Cassisi, G & Sarzi-Puttini, P 2014, 'Chronic widespread pain in spondyloarthritis', Reumatismo, vol. 66, no. 1, pp. 28-32. https://doi.org/10.4081/reumatismo.2014.761
Atzeni F, Boccassini L, Di Franco M, Alciati A, Marsico A, Cazzola M et al. Chronic widespread pain in spondyloarthritis. Reumatismo. 2014;66(1):28-32. https://doi.org/10.4081/reumatismo.2014.761
Atzeni, Fabiola ; Boccassini, L. ; Di Franco, M. ; Alciati, A. ; Marsico, A. ; Cazzola, M. ; Cassisi, G. ; Sarzi-Puttini, P. / Chronic widespread pain in spondyloarthritis. In: Reumatismo. 2014 ; Vol. 66, No. 1. pp. 28-32.
@article{c88b80f5065c47fb96fd178fa6f0381d,
title = "Chronic widespread pain in spondyloarthritis",
abstract = "The pain associated with spondyloarthritis (SpA) can be intense, persistent and disabling. It frequently has a multifactorial, simultaneously central and peripheral origin, and may be due to currently active inflammation, or joint damage and tissue destruction arising from a previous inflammatory condition. Inflammatory pain symptoms can be reduced by non-steroidal anti-inflammatory drugs, but many patients continue to experience moderate pain due to alterations in the mechanisms that regulate central pain, as in the case of the chronic widespread pain (CWP) that characterises fibromyalgia (FM). The importance of distinguishing SpA and FM is underlined by the fact that SpA is currently treated with costly drugs such as tumour necrosis factor (TNF) inhibitors, and direct costs are higher in patients with concomitant CWP or FM than in those with FM or SpA alone. Optimal treatment needs to take into account symptoms such as fatigue, mood, sleep, and the overall quality of life, and is based on the use of tricyclic antidepressants or selective serotonin reuptake inhibitors such as fluoxetine, rather than adjustments in the dose of anti-TNF agents or disease-modifying drugs.",
keywords = "Ankylosing spondylitis disease activity score, Bath ankylosing spondylitis disease activity index, Disease activity, Fibromyalgia, Prevalence, Spondyloarthritis",
author = "Fabiola Atzeni and L. Boccassini and {Di Franco}, M. and A. Alciati and A. Marsico and M. Cazzola and G. Cassisi and P. Sarzi-Puttini",
year = "2014",
doi = "10.4081/reumatismo.2014.761",
language = "English",
volume = "66",
pages = "28--32",
journal = "Reumatismo",
issn = "0048-7449",
publisher = "PAGEPRESS PUBL",
number = "1",

}

TY - JOUR

T1 - Chronic widespread pain in spondyloarthritis

AU - Atzeni, Fabiola

AU - Boccassini, L.

AU - Di Franco, M.

AU - Alciati, A.

AU - Marsico, A.

AU - Cazzola, M.

AU - Cassisi, G.

AU - Sarzi-Puttini, P.

PY - 2014

Y1 - 2014

N2 - The pain associated with spondyloarthritis (SpA) can be intense, persistent and disabling. It frequently has a multifactorial, simultaneously central and peripheral origin, and may be due to currently active inflammation, or joint damage and tissue destruction arising from a previous inflammatory condition. Inflammatory pain symptoms can be reduced by non-steroidal anti-inflammatory drugs, but many patients continue to experience moderate pain due to alterations in the mechanisms that regulate central pain, as in the case of the chronic widespread pain (CWP) that characterises fibromyalgia (FM). The importance of distinguishing SpA and FM is underlined by the fact that SpA is currently treated with costly drugs such as tumour necrosis factor (TNF) inhibitors, and direct costs are higher in patients with concomitant CWP or FM than in those with FM or SpA alone. Optimal treatment needs to take into account symptoms such as fatigue, mood, sleep, and the overall quality of life, and is based on the use of tricyclic antidepressants or selective serotonin reuptake inhibitors such as fluoxetine, rather than adjustments in the dose of anti-TNF agents or disease-modifying drugs.

AB - The pain associated with spondyloarthritis (SpA) can be intense, persistent and disabling. It frequently has a multifactorial, simultaneously central and peripheral origin, and may be due to currently active inflammation, or joint damage and tissue destruction arising from a previous inflammatory condition. Inflammatory pain symptoms can be reduced by non-steroidal anti-inflammatory drugs, but many patients continue to experience moderate pain due to alterations in the mechanisms that regulate central pain, as in the case of the chronic widespread pain (CWP) that characterises fibromyalgia (FM). The importance of distinguishing SpA and FM is underlined by the fact that SpA is currently treated with costly drugs such as tumour necrosis factor (TNF) inhibitors, and direct costs are higher in patients with concomitant CWP or FM than in those with FM or SpA alone. Optimal treatment needs to take into account symptoms such as fatigue, mood, sleep, and the overall quality of life, and is based on the use of tricyclic antidepressants or selective serotonin reuptake inhibitors such as fluoxetine, rather than adjustments in the dose of anti-TNF agents or disease-modifying drugs.

KW - Ankylosing spondylitis disease activity score

KW - Bath ankylosing spondylitis disease activity index

KW - Disease activity

KW - Fibromyalgia

KW - Prevalence

KW - Spondyloarthritis

UR - http://www.scopus.com/inward/record.url?scp=84902202670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902202670&partnerID=8YFLogxK

U2 - 10.4081/reumatismo.2014.761

DO - 10.4081/reumatismo.2014.761

M3 - Article

C2 - 24938193

AN - SCOPUS:84902202670

VL - 66

SP - 28

EP - 32

JO - Reumatismo

JF - Reumatismo

SN - 0048-7449

IS - 1

ER -